Anixa Biosciences (ANIX) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Anixa Biosciences (ANIX) over the past year, losing 28.2% versus a loss of 43.8%. Over five years, ANIX leads with a -38.7% price change compared with -99.9% for HURA. Anixa Biosciences is the larger company by market cap ($84.8 million vs $82.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | HURA |
|---|---|---|
| Share price | $2.44 | $1.25 |
| Market cap | $84.82M | $82.20M |
| 1-day change | -6.15% | -8.09% |
| YTD return | -21.79% | +65.13% |
| 1-year return | -43.78% | -28.16% |
| 5-year return | -38.69% | -99.91% |
| EPS (TTM) | $-0.32 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-10.93M | $-30.05M |
| 52-week high | $5.46 | $3.43 |
| 52-week low | $2.32 | $0.41 |
| Distance from 52-week high | -55.31% | -63.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +296.31% | +543.20% |
| Average volume | 282.29K | 329.76K |
| Shares outstanding | 34.76M | 65.76M |
| Employees | 4 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed ANIX by 15.6 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
ANIX vs HURA FAQ
Which is bigger, Anixa Biosciences or TuHURA Biosciences?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $84.82M compared with $82.20M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, ANIX or HURA?
HURA returned -28.16% over the past 12 months, compared with -43.78% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.